Calidi Biotherapeutics Public Offering Announcement
Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) has recently announced an intention to conduct a public offering of its common stock. This initiative aims to secure capital for advancing its innovative immunotherapy treatments. Calidi is at the forefront of biotechnology, creating unique therapies to empower the immune system's response against cancer.
Offering Details and Expectations
The proposed public offering includes shares of common stock and may involve pre-funded warrants. All offered shares will be provided by Calidi Biotherapeutics. This offering is under the provision of market conditions, which means while Calidi hopes to successfully navigate this process, the precise terms and timing remain uncertain.
Role of Placement Agent
In conjunction with this offering, Ladenburg Thalmann & Co. Inc. has been appointed as the exclusive placement agent, assisting with the offering's structure and potential outreach to investors. Their role is critical in facilitating the sale of shares and ensuring that all regulatory guidelines are met throughout this process.
Utilization of Proceeds
The proceeds from this offering are earmarked for working capital and general corporate purposes. This financial strategy indicates Calidi's commitment to furthering its research and development efforts, thereby enhancing its portfolio of immunotherapy solutions aimed at treating various oncology conditions.
Regulatory Compliance
A shelf registration statement pertaining to this offering was filed with the United States Securities and Exchange Commission (SEC) and has been declared effective. This means that Calidi Biotherapeutics can expedite the sale of its shares through a streamlined process, which can be advantageous in a dynamic financial market.
Investor Information
Interested investors are encouraged to review the preliminary prospectus that outlines the terms of the offering. This document, along with other relevant filings, is accessible on the SEC's website. For detailed inquiries, potential investors can reach out to Ladenburg Thalmann & Co. Inc. directly.
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage company focused on immuno-oncology. Its pioneering technology integrates stem cells to deliver targeted therapies designed to combat cancer. By utilizing allogeneic stem cells, Calidi aims to transport therapeutic agents, such as oncolytic viruses, directly to tumors, which may enhance treatment efficacy while prioritizing patient safety.
Innovative Approaches to Oncology
Calidi’s dual approach includes the development of both off-the-shelf therapies and personalized treatments for solid tumors, reinforcing its position as an innovator in the oncology space. With ongoing research, the company aspires not only to treat but potentially prevent the progression of metastatic disease.
Frequently Asked Questions
What is the purpose of Calidi's public offering?
The proceeds from the offering will be used for working capital and to support further research and development in immunotherapy.
Who is the placement agent for this offering?
Ladenburg Thalmann & Co. Inc. is serving as the exclusive placement agent for the offering.
Where can I find more information about the offering?
Interested parties can access the preliminary prospectus and other filings on the SEC's website.
What technology does Calidi Biotherapeutics develop?
Calidi develops stem cell-based immunotherapy solutions aimed at enhancing immune responses against cancerous tumors.
How does Calidi aim to improve cancer treatment?
Calidi's innovative therapies focus on the delivery of oncolytic viruses utilizing stem cells to target and treat tumors more effectively while ensuring patient safety.
